STONY BROOK, N.Y., March 23, 2022--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in cell-free, enzymatic DNA production, today announced that CEO Dr. James A. Hayward is invited to present at the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT. Dr. Haywards presentation will be available on-demand for the duration of the conference via the sign-up link: Sign up here to access the presentation<\/p>\n
During the virtual conference, investors will hear from executives from a wide range of sectors, including Biotech, Clean Energy, Electric Vehicles, Financial Services, Fintech & REITs, Gaming & Entertainment, Healthcare, Healthcare IT, Infrastructure, Shipping and Technology\/Media\/Telecom. The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts.<\/p>\n
This conference will be live on M-Vest. To attend, sign up to become an M-Vest member: Click Here to Reserve your seat<\/p>\n
About Applied DNA Sciences<\/p>\n
Applied DNA is commercializing LinearDNA, its proprietary, large-scale polymerase chain reaction (\"PCR\")-based manufacturing platform that allows for the large-scale cell-free production of specific DNA sequences.<\/p>\n
The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR T therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies.<\/p>\n
The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.<\/p>\n
Story continues<\/p>\n
Leveraging its deep expertise in nucleic acid-based technologies, the Company has also established safeCircle, a high-turnkey solution for population-scale COVID-19 testing. safeCircle is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies that increase testing efficiencies and provide for rapid turn-around-times.<\/p>\n
Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.<\/p>\n
The Company's common stock is listed on NASDAQ under the ticker symbol 'APDN,' and its publicly traded warrant is listed on OTC under the ticker symbol 'APPDW.'<\/p>\n
Applied DNA is a member of the Russell Microcap Index.<\/p>\n
View source version on businesswire.com: https:\/\/www.businesswire.com\/news\/home\/20220323005721\/en\/<\/a><\/p>\n Contacts<\/p>\n Investor Relations: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com<\/a> Web: http:\/\/www.adnas.com<\/a> Twitter: @APDN<\/p>\n <\/p>\n Continue reading here: STONY BROOK, N.Y., March 23, 2022--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in cell-free, enzymatic DNA production, today announced that CEO Dr. Continue reading
\nApplied DNA to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th 30th from 9:00 a.m....<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"